 |
|
|
|
|
Utah Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing UtahLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
EyeGate Pharmaceuticals, Inc
| | | | | Phone: | (617) 926-5000 | | Fax: | (617) 926-5050 | | Year Established: | 2011 | | Ticker: | EYEG | | Exchange: | NASDAQ | | Main Contact: | Nancy Lurker, President & CEO | | | | Company Description | | EyeGate, formerly Jade Therapeutics, is focused on developing therapeutics designed to address two major issues in ophthalmic medicine, patient compliance and patient throughput. EyeGate features a small, elegant, and easy-to-use device that delivers drugs non-invasively and quickly into the ocular tissues, which can dramatically increase the onset of action. The procedure only takes a few minutes and can be administered by all eye care practitioners. The EyeGate® II Delivery System is compatible with a wide
range of therapeutics and has the potential to address many anterior and posterior
segment diseases. Over 1,200 treatments have been performed with the EyeGate® II
Delivery System and it is the first ocular iontophoresis system to have completed Phase
II studies (Dry Eye and Uveitis), and a Phase III study (Dry Eye). | |
|
|
|
|
|
|
|
